low-downtime methods loose skin post-tirzepatide after weight loss Tighten Loose Skin After Weight

31.7% of patients achieved more than 15% weight loss compared to 0% placebo

You cannot partially activate it, stop midway, and come back later for the second half

Beyond blood sugar management, tirzepatide has become a promising solution for those striving for sustainable weight loss

Add-on to metformin with or without SGLT2 inhibitor SURPASS-3 (NCT03882970) was a 52-week open-label trial that randomized 1444 adult patients with type 2 diabetes mellitus with inadequate glycemic control on stable doses of metformin with or without SGLT2 inhibitor to the addition of subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg once weekly, or insulin degludec 100 units/mL once daily